Hydrogel comprising collagen crosslinked by platinum complex

The platinum crosslinked collagen hydrogel addresses the toxicity issues of existing collagen gels by using a platinum (II) complex for crosslinking, achieving high transparency and controlled properties, suitable for medical applications such as ophthalmology and cell culture.

WO2024242039A1PCT designated stage expired Publication Date: 2024-11-28WASEDA UNIV +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018273
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2024-05-17
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing collagen gels crosslinked with agents like glutaraldehyde, carbodiimide, or photocrosslinking agents have limitations due to toxicity and other issues, making them unsuitable for widespread medical use, particularly in the ophthalmology field, where a safe and transparent hydrogel is needed.

Method used

A platinum crosslinked collagen hydrogel is developed by incubating collagen with a platinum (II) complex at specific concentrations and pH levels, allowing for high transparency, low cytotoxicity, and the ability to remove excess crosslinking agents through dialysis, enabling controlled gel formation and reversibility.

Benefits of technology

The resulting hydrogel exhibits high transparency, controlled gel strength, and biodegradability, facilitating easy cell observation, in vivo injection, and safe removal, with potential applications in ophthalmology, as an artificial vitreous body, hemostatic agent, and scaffold for cell culture.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018273_28112024_PF_FP_ABST
    Figure JP2024018273_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The purpose is to develop a crosslinked collagen hydrogel that can be manufactured easily and has high transparency, high safety, and low toxicity. It was discovered that a platinum-crosslinked collagen hydrogel that is colorless, transparent, and free of cytotoxicity can be manufactured by incubating collagen of a predetermined concentration and a platinum(II) complex of a predetermined concentration in an environment of a predetermined pH, thus completing the present invention. Specifically, the present invention provides a hydrogel that is composed of platinum-crosslinked collagen in which collagen is crosslinked by a platinum(II) complex, and has a visible light transmittance of 60% or more as measured at an absorbance of 400 nm in a cell having an optical path length of 10 mm.
Need to check novelty before this filing date? Find Prior Art

Description

Hydrogels consisting of collagen cross-linked with platinum complexes

[0001] The present invention relates to a hydrogel made of collagen cross-linked with a platinum complex, its uses, and a method for producing the same.

[0002] Research is being conducted into novel hydrogels that can be used in medical applications, including the ophthalmological field (Patent Documents 1 and 2).

[0003] Collagen is a protein that mainly constitutes the dermis, ligaments, tendons, bones, and cartilage of vertebrates as collagen fibers, and is the main component of the extracellular matrix of multicellular animals. Collagen molecules have a triple helix structure formed by three polypeptide chains (α chains) helically intertwined.

[0004] If collagen is not crosslinked, it forms a cloudy, fibrous collagen gel (see Figure 1). Furthermore, research has been conducted into the preparation of collagen gels formed by crosslinking collagen with a crosslinking agent, with the aim of applying the gels as medical materials, etc. (Patent Documents 3 to 5). However, the collagen gels described in Patent Documents 3 to 5, which are formed using crosslinking agents such as glutaraldehyde, carbodiimide, genipin, or photocrosslinking agents, have limitations on their use in the human body due to issues such as toxicity, making them difficult to use within the body.

[0005] On the other hand, when the platinum complex cisplatin is dissolved in dimethyl sulfoxide (DMSO), ligand exchange occurs, resulting in the formation of [Pt(NH3)2(Cl)(DMSO)]. + It has been reported that [Pt(NH3)2(Cl)(DMSO)] inhibits collagen fiber formation and suppresses the cloudiness associated with fibrosis (Non-Patent Document 1). In addition, platinum complexes with substituted ligands have been shown to be less toxic than cisplatin (Non-Patent Documents 1-3). However, [Pt(NH3)2(Cl)(DMSO)] + It was not known that collagen could be cross-linked to form a hydrogel consisting of cross-linked collagen.

[0006] Zenda M. et al. , Chem Biol Drug Des 2015; 85: 519-526Fischer S. J. et al. , Neurotoxcology 2008; 29: 444-452 Raghavan R. et al. , Indian J Pharmacol 2015; 47: 322-324

[0007] JP 2017-121307 A JP 2020-150846 A International Publication Pamphlet: WO2005 / 079879 JP 2014-103985 A International Publication Pamphlet: WO2008 / 147867

[0008] The objective of the present invention was to develop a cross-linked collagen hydrogel that can be easily produced, has high transparency, is highly safe, and has low toxicity.

[0009] The present inventors have conducted extensive research and discovered that a platinum-crosslinked collagen hydrogel with high transparency and low cytotoxicity can be produced by incubating a predetermined concentration of collagen with a predetermined concentration of a platinum(II) complex under a predetermined pH environment, thereby completing the present invention. Furthermore, they have demonstrated that the crosslinking agent used in the production process can be removed by dialysis or other methods in the process of producing the platinum-crosslinked collagen hydrogel.

[0010] More specifically, the present invention provides a hydrogel comprising platinum-crosslinked collagen in which collagen is crosslinked with a platinum(II) complex, and having a visible light transmittance of 60% or more as measured at an absorbance of 400 nm in a cell with an optical path length of 10 mm.

[0011] In the hydrogel of the present invention, the collagen may be platinum-crosslinked collagen crosslinked with a platinum(II) complex, and the hydrogel may have a visible light transmittance of 60% or more as measured at absorbance in the range of 380 nm to 780 nm in a cell having an optical path length of 10 mm.

[0012] The hydrogel of the present invention may be a hydrogel in which the platinum (II) complex contains dimethyl sulfoxide (DMSO) as a ligand.

[0013] In the hydrogel of the present invention, the platinum(II) complex may be one in which at least one ligand of cis-diamminedichloroplatinum(II) (hereinafter also referred to as "cisplatin") and / or trans-diamminedichloroplatinum(II) (hereinafter also referred to as "transplatin") has been substituted with DMSO. That is, the platinum(II) complex may be one in which at least one chloride ion and / or ammine ligand of cis-diamminedichloroplatinum(II) and / or trans-diamminedichloroplatinum(II) has been substituted with DMSO. More preferably, at least one chloride ion has been substituted with DMSO. Particularly preferred platinum(II) complexes include the cis- or trans-form [Pt(NH3)2(Cl)(DMSO)]. + is.

[0014] In the hydrogel of the present invention, the collagen may be atelocollagen.

[0015] The hydrogel of the present invention may be a hydrogel for use as an artificial vitreous body, a hemostatic agent, a sustained-release drug carrier, a tissue replacement material, or a scaffold material for cell culture.

[0016] The present invention also provides a material for treating ophthalmic diseases, comprising the hydrogel.

[0017] The present invention also provides an artificial vitreous body comprising the hydrogel.

[0018] The present invention also provides a hemostatic agent comprising the hydrogel.

[0019] The present invention also provides a scaffold material for cell culture, which comprises the hydrogel.

[0020] The present invention also provides a method for producing a hydrogel, which comprises the step of mixing collagen and a platinum(II) complex and incubating the mixture.

[0021] The method for producing a hydrogel of the present invention may be a production method comprising the step of incubating the collagen having a concentration in the range of 1.0 to 4.0 mg / mL and the platinum(II) complex having a concentration in the range of 25 μM to 1 mM in an environment having a pH in the range of 5.0 to 8.0.

[0022] The present invention also provides a method for producing the hydrogel, comprising: (a) a step of incubating collagen having a concentration in the range of 1.0 to 4.0 mg / mL and a platinum(II) complex having a concentration in the range of 25 μM to 1 mM in an environment with a pH of less than 5.0; and (b) a step of changing the pH environment to 5.0 to 8.0 to induce gelation.

[0023] The production method may include, between steps (a) and (b), a step (a') of removing free platinum(II) complexes by dialysis in an environment with a pH of less than 5.0.

[0024] According to the present invention, a platinum-crosslinked collagen hydrogel can be provided which can be easily produced, has low toxicity, and has high transparency.

[0025] The hydrogel of the present invention has the following characteristics: high transparency; gel formation can be controlled by pH; gel strength can be controlled by the concentration of platinum(II) complex; gelation is reversible and the gel can be dissolved; and unreacted crosslinker can be removed.

[0026] This offers the following advantages: (1) Even in thick 3D cultures, cell observation is easy and good data can be obtained efficiently. (2) After being injected into a living body, such as the eyeball, and gelling, it can be dissolved and removed. (3) The hardness of the gel can be adjusted to suit the application. Therefore, it is expected that biodegradability can be adjusted. (4) There is no toxicity due to unreacted crosslinker.

[0027] Figure 1 shows a schematic diagram of fibrillated collagen (bottom left) and platinum-crosslinked collagen crosslinked with a cisplatin-DMSO complex (bottom right). The cisplatin-DMSO complex inhibits collagen fibrillation by crosslinking collagen, preventing the formation of a cloudy hydrogel (fibrous collagen gel). Figure 2 shows the evaluation results of the gelation ability of platinum-crosslinked collagen when a mixture of atelocollagen and various concentrations of cisplatin-DMSO complex was incubated in a pH 7.4 buffer solution at 37°C for 30 minutes. The arrowheads in the figure indicate stainless steel balls. Figure 3 shows a graph of the light transmittance from 200 to 900 nm for a fibrillated atelocollagen hydrogel (solid line) and a platinum-crosslinked atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex (dashed line). Figure 4 shows the results of evaluating the ability to form a fibrillated atelocollagen hydrogel (top row) and a platinum-crosslinked atelocollagen hydrogel (bottom row) when various concentrations of atelocollagen (top row) and a mixture of atelocollagen and a cisplatin-DMSO complex (bottom row) were incubated in a pH 7.4 buffer solution at 37°C for 30 minutes. The arrowheads in the figure indicate stainless steel balls. Figure 5 shows the results of evaluating the ability to form a fibrillated atelocollagen hydrogel (top row) and a mixture of atelocollagen and a cisplatin-DMSO complex (bottom row) when incubated in various pH environments at 37°C for 30 minutes. The arrowheads in the figure indicate stainless steel balls. Figure 6 shows the results of evaluating the ability to form a platinum-crosslinked atelocollagen hydrogel when a mixture of atelocollagen and a cisplatin-DMSO complex was incubated in a pH 7.4 buffer solution at 37°C for 30 minutes under various ionic strength environments. The arrowheads in the figures indicate stainless steel balls. Figure 7 shows the results of an investigation into the gelation time when a mixture of atelocollagen and a cisplatin-DMSO complex was incubated in a pH 7.4 buffer solution at 37°C for 5 to 20 minutes. The arrowheads in the figures indicate stainless steel balls. Figure 8 shows the results of an investigation into the effect of temperature on the gelation ability when a mixture of atelocollagen and a cisplatin-DMSO complex was incubated in a pH 7.4 buffer solution at 4 to 37°C for 30 minutes. The arrowheads in the figures indicate stainless steel balls.Figure 9 shows the evaluation results of gelation ability of a platinum-crosslinked atelocollagen solution prepared by dialyzing a mixture of atelocollagen and cisplatin-DMSO complex in 1 mM HCl aqueous solution overnight at 4°C, and of the resulting solution after changing its pH to 7.4 and incubating at 37°C for 30 minutes. Figure 9A shows the state before pH adjustment, and Figure 9B shows the state after pH adjustment. The arrowheads in the figures indicate stainless steel balls. Figure 10 shows the evaluation results of gelation ability of mixtures of atelocollagen and various concentrations of transplatin-DMSO complex incubated in a pH 7.4 buffer solution at 37°C for 30 minutes. The arrowheads in the figures indicate stainless steel balls. Figure 11 shows the evaluation results of platinum-crosslinked atelocollagen forming ability of mixtures of atelocollagen and various concentrations of transplatin-DMSO complex incubated in a pH 7.4 buffer solution at 37°C for 30 minutes. The arrowheads in the figures indicate stainless steel balls. Figure 12 shows the results of evaluating the platinum-crosslinked atelocollagen hydrogel-forming ability of a mixture of atelocollagen and a transplatin-DMSO complex incubated at 37°C for 30 minutes under various pH conditions. The arrowhead in the figure indicates a stainless steel ball. Figure 13 shows the results of evaluating the platinum-crosslinked collagen hydrogel-forming ability of a mixture of atelocollagen and a transplatin-DMSO complex incubated in a pH 7.4 buffer solution at 37°C for 30 minutes under various ionic strength conditions. The arrowhead in the figure indicates a stainless steel ball. Figure 14 shows the results of examining the hydrogel formation time of a mixture of atelocollagen and a transplatin-DMSO complex incubated in a pH 7.4 buffer solution at 37°C for 5 to 15 minutes. The arrowhead in the figure indicates a stainless steel ball. Figure 15 shows the results of examining the temperature dependence of gelation of a mixture of atelocollagen and a transplatin-DMSO complex incubated in a pH 7.4 buffer solution at 4 to 37°C for 30 minutes. The arrowhead in the figure indicates a stainless steel ball. 16 shows the results of evaluating the thermal stability of a fibrous atelocollagen hydrogel and a platinum-crosslinked atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex when heated. The arrowheads in the figure indicate stainless steel balls.Figure 17 shows the results of an investigation into the heat shrinkage of a fibrous atelocollagen hydrogel and a platinum-crosslinked atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex after heating. Figure 17A shows the state of the fibrous atelocollagen gel, Figure 17B shows the state of the crosslinked atelocollagen gel before heating, and Figure 17C shows the state of the crosslinked atelocollagen gel after 30 minutes of heating. Figure 18 shows phase-contrast and fluorescence microscopic images of HT-1080 cells stained with Hoechst 33342 and calcein-AM after 1.5 to 67 hours of culture on a fibrous atelocollagen hydrogel or a platinum-crosslinked atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex. Figure 19 shows a graph evaluating cell proliferation activity by counting the number of cells cultured on a fibrous atelocollagen hydrogel or a platinum-crosslinked atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex for 1.5 to 67 hours. Figure 20 shows micrographs of hematoxylin-eosin (HE)-stained gel sections of HT-1080 cells seeded on a fibrous atelocollagen hydrogel or a platinum-crosslinked atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex, cultured for four days. Figure 20A shows a micrograph of the fibrous atelocollagen hydrogel, and Figure 20B shows a micrograph of the platinum-crosslinked atelocollagen hydrogel. Figure 21 shows confocal fluorescence micrographs of 3D cell aggregates formed after mixing MDCK cells derived from a canine renal tubular cell line, embedding them in a fibrous gel (Figure 21A) and a platinum(II) complex-crosslinked gel (Figure 21B), and culturing them for six days. Figure 21C shows the relationship between the depth of field and fluorescence intensity after mixing MDCK cells derived from a canine renal tubular cell line, embedding them in a fibrous gel (denoted as FG) and a platinum(II) complex-crosslinked gel (denoted as PCG), and culturing them for six days. Figure 22 shows the results of an investigation into gel dissolution of a platinum(II) complex cross-linked gel by adding reduced glutathione, and Figure 23 shows the results of an investigation into the relationship between the amount of platinum(II) complex added and adjustment of gel hardness.Figure 23A shows the degree of deformation of a 50 μM transplatin-DMSO cross-linked collagen gel, Figure 23B shows the degree of deformation of a 100 μM transplatin-DMSO cross-linked collagen gel, Figure 23C shows the degree of deformation of a 300 μM transplatin-DMSO cross-linked collagen gel, Figure 23D shows the degree of deformation of a 500 μM transplatin-DMSO cross-linked collagen gel, and Figure 23E shows the degree of deformation of a 1 mM transplatin-DMSO cross-linked collagen gel when pressed down with a spatula from above. Atelocollagen gels containing transplatin-DMSO at various concentrations (50 to 800 μM) were prepared, and the elastic modulus was measured using a universal testing machine.

[0028] 1. Definitions As used herein, the term "platinum(II) complex" refers to a platinum complex that has the ability to crosslink collagen. Specifically, the platinum(II) complex refers to a complex having dimethyl sulfoxide (DMSO) as a ligand, and more specifically refers to a complex in which at least one ligand of cis-diamminedichloroplatinum(II) (hereinafter also referred to as "cisplatin") has been substituted with DMSO, more preferably a complex in which at least one chloride ion and / or ammine of cisplatin has been substituted with DMSO (also referred to as a "cisplatin-DMSO complex" herein), or a complex in which at least one ligand of trans-diamminedichloroplatinum(II) (hereinafter also referred to as "transplatin") has been substituted with DMSO, more preferably a complex in which at least one chloride ion and / or ammine of transplatin has been substituted with DMSO (also referred to as a "transplatin-DMSO complex" herein). More specifically, the "cisplatin-DMSO complex" is a cis-type [Pt(NH3)2(Cl)(DMSO)] complex produced by dissolving the platinum complex cisplatin in dimethyl sulfoxide (DMSO). + "Transplatin-DMSO complex" refers to the trans-form [Pt(NH3)2(Cl)(DMSO)] produced by dissolving transplatin in dimethyl sulfoxide (DMSO). + It includes:

[0029] As used herein, the term "platinum-crosslinked collagen" refers to a collagen derivative obtained by crosslinking collagen with the aforementioned "platinum (II) complex" (see Figure 1).

[0030] As used herein, the term "platinum-crosslinked collagen hydrogel" refers to a hydrogel obtained by crosslinking collagen with the platinum(II) complex. More specifically, the term refers to a hydrogel obtained by placing an aqueous solution containing platinum-crosslinked collagen obtained by crosslinking collagen with the platinum(II) complex in an environment of pH 5.0 to 8.0.

[0031] In this specification, the term "consisting of" is used to mean "formed" and is distinguished from "consisting only of," which is limited to certain components.

[0032] 2. Hydrogel Made of Platinum-Crosslinked Collagen One embodiment of the present invention is a hydrogel made of platinum-crosslinked collagen (also referred to as "platinum-crosslinked collagen hydrogel").

[0033] The collagen gel of the present invention comprises platinum-crosslinked collagen in which collagen is crosslinked with a platinum(II) complex, and has a visible light transmittance of 60% or more as measured at absorbance at 400 nm, preferably 380 nm to 780 nm, in a cell with an optical path length of 10 mm, thereby providing a hydrogel with high transparency in the visible light range.

[0034] The platinum-crosslinked collagen hydrogel of the present invention can be produced by a production method including the step of incubating a predetermined concentration of collagen and a predetermined concentration of platinum(II) complex under a predetermined pH environment. As shown in the Examples below, preferred production conditions include a collagen concentration of preferably 1.0 to 4.0 mg / mL, more preferably 1.5 to 4.0 mg / mL, and even more preferably 1.5 to 3.5 mg / mL, a platinum(II) complex concentration of preferably 25 to 200 μM, more preferably 50 to 200 μM, even more preferably 50 to 150 μM, and most preferably 100 to 200 μM, and a pH of preferably 5.0 to 8.0, more preferably 6.0 to 8.0, and even more preferably 7.0 to 8.0, with pH 7.4 being particularly preferred.

[0035] Collagen can be used as a raw material for producing the platinum-crosslinked collagen hydrogel of the present invention, and preferably, fibril-forming collagen can be used. Several types of fibril-forming collagen are known, including type I and type II, and any of these types can be used for producing the hydrogel of the present invention. Type I collagen is particularly preferred from the viewpoint of its high gelling ability. Furthermore, collagen derived from vertebrates such as bovine, equine, porcine, rabbit, mouse, monkey, human, rainbow trout, tilapia, and catfish can be used for producing the hydrogel of the present invention.

[0036] Generally, non-triple helix regions (telopeptides) exist at the ends of the collagen triple helix, and these regions are the main antigenic sites of collagen. It is known that the antigenicity of collagen is significantly reduced when the telopeptides are removed by enzymatic treatment, and collagen from which the telopeptides have been removed by enzymatic treatment is called atelocollagen. Atelocollagen can be preferably used in the production of the hydrogel of the present invention.

[0037] Collagen and atelocollagen are commercially available and can be used in the production.

[0038] The platinum (II) complex used to produce platinum-crosslinked collagen may be either or both of a cisplatin-DMSO complex and a transplatin-DMSO complex.

[0039] As shown in the examples below, the hydrogel of the present invention has the following characteristics: high transparency; gel formation can be controlled by pH; gel strength can be controlled by the concentration of the platinum(II) complex; gelation is reversible, and the gel can be dissolved; and unreacted crosslinker can be removed.

[0040] This offers the following advantages: (1) Even in thick 3D cultures, cell observation is easy and good data can be obtained efficiently. (2) After being injected into a living body, such as the eyeball, and gelling, it can be dissolved and removed. (3) The hardness of the gel can be adjusted to suit the application, which is expected to enable adjustment of biodegradability. (4) There is no toxicity due to unreacted crosslinker.

[0041] The platinum-crosslinked collagen hydrogel of the present invention has high transparency, no cytotoxicity, and exhibits high safety, and therefore can be used as a material for treating ophthalmic diseases such as macular hole, retinal detachment, and retinal break, as well as artificial vitreous, a hemostatic agent (preferably a tamponade material), a sustained-release drug carrier, a tissue replacement material, or a scaffold material for cell culture. In particular, the platinum-crosslinked collagen hydrogel of the present invention can be prepared by crosslinking collagen with a platinum(II) complex, and then removing the free platinum(II) complex by dialysis before the platinum-crosslinked collagen forms a hydrogel. This suppresses cytotoxicity derived from the crosslinker, allowing it to be safely used in vivo as a material for treating ophthalmic diseases and the like, as well as in vitro cell culture. Furthermore, since the induction of gelation can be appropriately controlled by adjusting the pH environment, the platinum-crosslinked collagen of the present invention can be injected into a living body in a sol state and gelled in vivo. Therefore, a therapeutic material that can reduce the burden on the recipient when applied in vivo can be provided. Furthermore, as shown in the examples below, the gel strength of the platinum-crosslinked collagen of the present invention can be controlled by the concentration of the platinum(II) complex, and the gelation is reversible, making it possible to dissolve the gel.

[0042] 3. Method for Producing Platinum-Crosslinked Collagen Hydrogel Another embodiment of the present invention is a method for producing a platinum-crosslinked collagen hydrogel.

[0043] As described above, the method for producing a platinum-crosslinked collagen hydrogel includes the step of incubating a predetermined concentration of collagen and a predetermined concentration of a platinum(II) complex in an environment of a predetermined pH.

[0044] In the method for producing a platinum-crosslinked collagen hydrogel, the collagen concentration is preferably in the range of 1.0 to 4.0 mg / mL, the platinum(II) complex concentration is in the range of 25 to 200 μM, and the pH is in the range of 5.0 to 8.0. The collagen concentration is more preferably 1.5 to 4.0 mg / mL, and even more preferably 1.5 to 3.5 mg / mL. The platinum(II) complex concentration is more preferably 50 to 200 μM, even more preferably 50 to 150 μM, and most preferably 100 to 200 μM. The pH is more preferably 6.0 to 8.0, even more preferably 7.0 to 8.0, with pH 7.4 being particularly preferred.

[0045] The collagen used as the raw material for the platinum-crosslinked collagen hydrogel is preferably atelocollagen, and commercially available products can be used.

[0046] The platinum(II) complex may be either or both of a cisplatin-DMSO complex or a transplatin-DMSO complex.

[0047] The method for producing the hydrogel may also include the steps of: (a) incubating collagen having a concentration in the range of 1.0 to 4.0 mg / mL and a platinum(II) complex having a concentration in the range of 25 to 200 μM in an environment with a pH of less than 5.0; and (b) changing the pH environment to 5.0 to 8.0 to induce gelation. A more preferred pH environment in step (a) is greater than 1.0 and less than 5.0, even more preferably in the range of 2.0 to 4.0, with a pH of 3.0 being particularly preferred. A more preferred pH environment in step (b) is in the range of 6.0 to 8.0, even more preferably in the range of 7.0 to 8.0, with a pH of 7.4 being particularly preferred.

[0048] Furthermore, the production method may include, between steps (a) and (b), a step (a') of removing free platinum(II) complexes by dialysis in an environment with a pH of less than 5.0. The pH environment in step (a') may be the same as or different from that in step (a). A more preferred pH environment in step (a') is a pH greater than 1.0 and less than 5.0, even more preferably a pH in the range of 2.0 to 4.0, with a pH of 3.0 being particularly preferred.

[0049] The present invention will be explained in more detail below with reference to examples and comparative examples, but modifications can be made as appropriate without departing from the spirit of the present invention. Therefore, the scope of the present invention should not be construed as being limited by the specific examples shown below.

[0050] I. Materials and Methods 1. Evaluation of Gelation Ability (1) Atelocollagen (final concentration 2.5 mg / mL) was mixed with various concentrations of cisplatin-DMSO complex solutions (final concentrations 0-200 μM) to prepare atelocollagen / cisplatin-DMSO complex mixtures containing physiological phosphate buffer [30 mM phosphate buffer (pH 7.4), 120 mM NaCl], and incubated at 37°C for 30 minutes. Diameter: 1.5 mm, specific gravity: 7.8 g / cm 3 The formation of a hydrogel was evaluated based on whether the stainless steel ball was retained on the interface. The results are shown in Figure 2.

[0051] 2. Evaluation of Hydrogel Transparency A fibrous atelocollagen hydrogel (2.5 mg / mL atelocollagen, 0 μM cisplatin-DMSO complex, pH 7.4) and a platinum-crosslinked atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex (2.5 mg / mL atelocollagen, 100 μM cisplatin-DMSO complex, pH 7.4) were prepared in a cell by incubation at 37°C for 30 minutes, and the transmittance of light with wavelengths of 200-900 nm was measured using a spectrophotometer U5100 (Hitachi). The results are shown in Figure 3.

[0052] 3. Evaluation of Atelocollagen Concentration (1) Atelocollagen (final concentration 0.1-2.5 mg / mL) was mixed with 10 mM cisplatin-DMSO complex solution (final concentration 100 μM) to prepare an atelocollagen / cisplatin-DMSO complex mixture containing physiological phosphate buffer [30 mM phosphate buffer (pH 7.4), 120 mM NaCl] and incubated at 37°C for 30 minutes. The formation of a hydrogel was evaluated based on whether a stainless steel ball was retained at the interface. As a control, an atelocollagen solution (final concentration 0.1-2.5 mg / mL) was prepared in the same manner except that it did not contain the cisplatin-DMSO complex solution, and the hydrogel-forming ability of the fibrillated atelocollagen was evaluated. The results are shown in Figure 4.

[0053] 4. pH Evaluation (1) Atelocollagen (final concentration 2.5 mg / mL) was mixed with 10 mM cisplatin-DMSO complex solution (final concentration 100 μM) to prepare atelocollagen / cisplatin-DMSO complex mixtures containing buffer solutions of various pH values ​​[30 mM buffer, 120 mM NaCl]. These mixtures were then incubated at 37°C for 30 minutes. The 30 mM buffer solutions used were citrate buffer at pH 4.0 and pH 5.0, phosphate buffer at pH 6.0, pH 7.4, and pH 8.0, and borate buffer at pH 9.0. Hydrogel formation was evaluated based on whether a stainless steel ball was retained at the interface. As a control, the pH was changed in the same manner except that the cisplatin-DMSO complex solution was not included, and the ability to form a fibrillated atelocollagen hydrogel was evaluated. The results are shown in Figure 5.

[0054] 5. Ionic Strength Evaluation (1) Atelocollagen (final concentration 2.5 mg / mL) was mixed with a 10 mM cisplatin-DMSO complex solution (final concentration 100 μM) to prepare atelocollagen / cisplatin-DMSO complex mixtures containing 30 mM phosphate buffer (pH 7.4) and various concentrations of NaCl. The mixtures were incubated at 37°C for 30 minutes. The NaCl concentrations were 0 mM, 70 mM, 120 mM, or 170 mM. Whether a stainless steel ball was retained on the interface was used as an indicator to evaluate whether a hydrogel had formed. The results are shown in Figure 6.

[0055] 6. Evaluation of Gelation Time (1) Atelocollagen (final concentration 2.5 mg / mL) was mixed with a 10 mM cisplatin-DMSO complex solution (final concentration 100 μM) to prepare an atelocollagen / cisplatin-DMSO complex mixture containing physiological phosphate buffer [30 mM phosphate buffer (pH 7.4), 120 mM NaCl], and the mixture was incubated at 37°C for 5, 10, 15, or 20 minutes. The formation of a hydrogel was evaluated based on whether a stainless steel ball was retained at the interface. The results are shown in Figure 7.

[0056] 7. Gelation Temperature Evaluation (1) Atelocollagen (final concentration 2.5 mg / mL) was mixed with a 10 mM cisplatin-DMSO complex solution (final concentration 100 μM) to prepare an atelocollagen / cisplatin-DMSO complex mixture containing physiological phosphate buffer [30 mM phosphate buffer (pH 7.4), 120 mM NaCl], and the mixture was incubated at 4°C, 20°C, or 37°C for 30 minutes. Whether a stainless steel ball was retained on the interface was used as an indicator to evaluate whether a hydrogel had formed. The results are shown in Figure 8.

[0057] 8. Investigation of Dialysis Removal Method for Free Platinum Complexes. An acidic atelocollagen solution (final concentration 4.9 mg / mL) and a 10 mM cisplatin-DMSO complex solution (final concentration 100 μM) were mixed and left to stand at 4°C for 3 days. This atelocollagen / cisplatin-DMSO complex mixed solution was transferred to a dialysis tube (molecular weight cutoff 12,000-14,000), immersed in 1 mM HCl aqueous solution, and left to stand overnight at 4°C. This atelocollagen / cisplatin-DMSO complex mixed solution (final concentration 2.5 mg / mL) was mixed with 1 mM HCl aqueous solution or 10x physiological phosphate buffer [final concentration 30 mM phosphate buffer (pH 7.4), final concentration 120 mM NaCl] and incubated at 37°C for 30 minutes. The formation of a hydrogel was evaluated based on whether a stainless steel ball was retained at the interface. The results are shown in Figure 9.

[0058] 9. Evaluation of gelation ability (2) Atelocollagen (final concentration 2.5 mg / mL) was mixed with various concentrations of transplatin-DMSO complex solutions (final concentrations 0-200 μM) to prepare atelocollagen / transplatin-DMSO complex mixtures containing physiological phosphate buffer [30 mM phosphate buffer (pH 7.4), 120 mM NaCl], and the mixtures were incubated at 37°C for 30 minutes. The formation of a hydrogel was evaluated based on whether a stainless steel ball was retained at the interface. The results are shown in Figure 10.

[0059] 10. Evaluation of Atelocollagen Concentration (2) Atelocollagen (final concentration 0.1-2.5 mg / mL) was mixed with a 10 mM transplatin-DMSO complex solution (final concentration 100 μM) to prepare an atelocollagen / transplatin-DMSO complex mixture containing physiological phosphate buffer [30 mM phosphate buffer (pH 7.4), 120 mM NaCl], and the mixture was incubated at 37°C for 30 minutes. The formation of a hydrogel was evaluated based on whether a stainless steel ball was retained at the interface. The results are shown in Figure 11.

[0060] 11. pH Evaluation (2) Atelocollagen (final concentration 2.5 mg / mL) was mixed with a 10 mM transplatin-DMSO complex solution (final concentration 100 μM) to prepare atelocollagen / transplatin-DMSO complex mixtures containing physiological buffer solutions of various pH values ​​[30 mM buffer, 120 mM NaCl]. These mixtures were then incubated at 37°C for 30 minutes. The formation of hydrogels was evaluated based on whether the stainless steel balls remained on the interface. The 30 mM buffer solutions used were citrate buffer at pH 4.0 and pH 5.0, phosphate buffer at pH 6.0, pH 7.4, and pH 8.0, and borate buffer at pH 9.0. The results are shown in Figure 12.

[0061] 12. Ionic Strength Evaluation (2) Atelocollagen (final concentration 2.5 mg / mL) was mixed with a 10 mM transplatin-DMSO complex solution (final concentration 100 μM) to prepare atelocollagen / transplatin-DMSO complex mixtures containing 30 mM phosphate buffer (pH 7.4) and various concentrations of NaCl. The mixtures were incubated at 37°C for 30 minutes. NaCl concentrations were 20 mM, 70 mM, 120 mM, or 170 mM. Whether a stainless steel ball was retained on the interface was used as an indicator to evaluate whether a hydrogel had formed. The results are shown in Figure 13.

[0062] 13. Evaluation of Gelation Time (2) Atelocollagen (final concentration 2.5 mg / mL) was mixed with a 10 mM transplatin-DMSO complex solution (final concentration 100 μM) to prepare an atelocollagen / transplatin-DMSO complex mixture containing physiological phosphate buffer [30 mM phosphate buffer (pH 7.4), 120 mM NaCl], and the mixture was incubated at 37°C for 5, 10, or 15 minutes. The formation of a hydrogel was evaluated based on whether a stainless steel ball was retained at the interface. The results are shown in Figure 14.

[0063] 14. Gelation Temperature Evaluation (2) Atelocollagen (final concentration 2.5 mg / mL) was mixed with a 10 mM transplatin-DMSO complex solution (final concentration 100 μM) to prepare an atelocollagen / transplatin-DMSO complex mixture containing physiological phosphate buffer [30 mM phosphate buffer (pH 7.4), 120 mM NaCl], and the mixture was incubated at 4°C, 24°C, or 37°C for 30 minutes. The formation of a hydrogel was evaluated based on whether a stainless steel ball was retained at the interface. The results are shown in Figure 15.

[0064] 15. Evaluation of Thermal Stability of Hydrogels A fibrous atelocollagen hydrogel (0 μM cisplatin-DMSO complex) with a final concentration of 2.5 mg / mL and an atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex (100 μM cisplatin-DMSO complex) with a final concentration of 2.5 mg / mL were prepared. The prepared atelocollagen hydrogels were heated at 50°C, 60°C, or 70°C for 5 minutes each, and a stainless steel ball was examined for retention on the interface. The results are shown in Figure 16.

[0065] 16. Study of the heat shrinkage of the hydrogel. Atelocollagen hydrogels crosslinked with a cisplatin-DMSO complex at a final concentration of 2.5 mg / mL (100 μM cisplatin-DMSO complex) were prepared in a silicone support with a diameter of 10 mm and a thickness of 5 mm. The platinum-crosslinked atelocollagen hydrogels were immersed in 80°C boiling water for 30 minutes. The results are shown in Figure 17.

[0066] 17. Evaluation of cytotoxicity and cell proliferation activity 4.0 mg / mL fibrous atelocollagen hydrogel or 4.0 mg / mL platinum-crosslinked atelocollagen hydrogel crosslinked with cisplatin-DMSO complex was prepared in a 35 mm diameter culture dish. 8 × 10 cells were placed on the prepared fibrous atelocollagen hydrogel or platinum-crosslinked atelocollagen hydrogel. 4 HT-1080 cells were seeded at 1 / dish and cultured in DMEM containing 10% FBS at 37°C. After culturing for 1.5 to 67 hours, the cells were stained with Hoechst 33342 and calcein-AM for 30 minutes and observed under a fluorescence microscope. Phase contrast and fluorescence microscope images taken at each time point are shown in Figure 18.

[0067] The number of cells per field of view shown in Figure 18 was also counted. The number of cells was calculated by counting cells in five randomly selected fields of view and averaging the results. The results are shown in Figure 19.

[0068] 18. Evaluation of cell invasion A 4 mg / mL fibrous atelocollagen hydrogel or a 4 mg / mL platinum-crosslinked atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex was prepared in a 24-well plate transwell insert. 3 × 10 cells were placed on the prepared fibrous atelocollagen hydrogel or platinum-crosslinked atelocollagen gel. 4 HT-1080 cells were seeded at 1 / well and cultured in DMEM containing 10% FBS at 37°C for 4 days. The medium was changed once on the second day of culture. After 4 days of culture, the cells were fixed with 4% paraformaldehyde, the hydrogel was embedded in paraffin, and sections were prepared. The sections were stained with hematoxylin and eosin (HE) and observed under a microscope. The results are shown in Figure 20.

[0069] II. Results 1. Evaluation of gelation ability (1) At 37°C, the atelocollagen / cisplatin-DMSO complex mixture gelled at cisplatin-DMSO concentrations except for 25 μM, and a stainless steel ball was held at the interface. Furthermore, the transparency of the collagen hydrogel increased with increasing cisplatin-DMSO complex concentration, and almost no cloudiness was observed at concentrations above 50 μM (Figure 2).

[0070] 2. Evaluation of hydrogel transparency Platinum-crosslinked atelocollagen hydrogels crosslinked with cisplatin-DMSO complexes exhibited higher transparency in the visible light range (approximately the same transparency as transparent plastics such as polystyrene) compared to fibrillated atelocollagen hydrogels (Figure 3). This result suggests that although the addition of cisplatin-DMSO complexes to atelocollagen inhibits atelocollagen fibrillation, the atelocollagen acquires high-molecular-weight physical properties due to crosslinking (Figure 1).

[0071] 3. Evaluation of atelocollagen concentration (1) Gelation of fibrous atelocollagen was observed at concentrations of 1.5 mg / mL or higher, and the hydrogel was cloudy (Figure 4). Gelation of platinum-crosslinked atelocollagen crosslinked with cisplatin-DMSO complex was observed at concentrations of 1.0 mg / mL or higher, and the hydrogel was transparent (Figure 4).

[0072] 4. pH Evaluation (1) Gelation of fibrous atelocollagen was observed at pH 6.0 or higher, and the hydrogel was cloudy (Figure 5). Platinum-crosslinked atelocollagen crosslinked with cisplatin-DMSO complex was observed at pH 5.0 or higher, and the hydrogel showed high transparency (Figure 5). Cloudiness was observed at pH 9.0.

[0073] 5. Ionic strength evaluation (1) Platinum-crosslinked atelocollagen crosslinked with cisplatin-DMSO complex was observed to gel in 30 mM phosphate buffer and at all concentrations of NaCl: 0 mM, 70 mM, 120 mM, and 170 mM, i.e., at all concentrations of total ionic strength: 50 mM, 100 mM, 150 mM, and 200 mM (Figure 6). However, at 0 mM and 70 mM NaCl, the hydrogel became cloudy.

[0074] 6. Evaluation of gelation time (1) Platinum-crosslinked atelocollagen crosslinked with cisplatin-DMSO complex was observed to gel after 15 minutes at 37°C, and the hydrogel showed high transparency (Figure 7).

[0075] 7. Evaluation of Gelation Temperature (1) Platinum-crosslinked atelocollagen crosslinked with cisplatin-DMSO complex was observed to gel after 30 minutes at all temperatures of 4°C, 20°C, and 37°C, and the hydrogel showed high transparency (Figure 8).

[0076] 8. Dialysis removal of free platinum complexes Platinum-crosslinked atelocollagen crosslinked with cisplatin-DMSO complexes did not gel in 1 mM HCl aqueous solution, but gelation occurred after 30 minutes at 37°C when the pH was changed to 7.4, and the hydrogel exhibited high transparency (Figure 9).

[0077] 9. Evaluation of gelation ability (2) The atelocollagen / transplatin-DMSO complex mixture gelled at 37°C at transplatin-DMSO concentrations except for 10 μM and 25 μM, and a stainless steel ball was held at the interface (Figure 10). At a transplatin-DMSO concentration of 25 μM, gelation occurred to a moderate extent, and the stainless steel ball was held near the center. Furthermore, as the transplatin-DMSO complex concentration increased, the transparency of the collagen hydrogel increased, and at concentrations above 25 μM, almost no cloudiness was observed (Figure 10).

[0078] 10. Evaluation of Atelocollagen Concentration (2) Platinum-crosslinked atelocollagen crosslinked with transplatin-DMSO complex was observed to gel at a concentration of 1.5 mg / mL or higher, and the hydrogel showed high transparency (FIG. 11).

[0079] 11. pH Evaluation (2) Platinum-crosslinked atelocollagen crosslinked with transplatin-DMSO complex was observed to gel at pH 6.0 or higher, and the hydrogel showed high transparency (Figure 12). However, at pH 9.0, cloudiness was observed.

[0080] 12. Ionic Strength Evaluation (2) Platinum-crosslinked atelocollagen crosslinked with transplatin-DMSO complex was observed to gel in 30 mM phosphate buffer and NaCl concentrations of 20 mM, 70 mM, 120 mM, and 170 mM, i.e., total ionic strengths of 50 mM, 100 mM, 150 mM, and 200 mM (Figure 13). However, at 20 mM NaCl, the hydrogel became cloudy.

[0081] 13. Evaluation of Gelation Time (2) Platinum-crosslinked atelocollagen crosslinked with transplatin-DMSO complex was observed to gel after 15 minutes at 37°C, and the hydrogel showed high transparency (Figure 14).

[0082] 14. Gelation Temperature Evaluation (2) Platinum-crosslinked atelocollagen crosslinked with transplatin-DMSO complex was observed to undergo hydrogelation after 30 minutes at 24°C and 37°C, and the hydrogel showed high transparency (Figure 15). No gelation was observed after 30 minutes at 4°C (Figure 15).

[0083] 15. Evaluation of thermal stability of hydrogels The fibrous atelocollagen hydrogel (0 μM cisplatin-DMSO complex) was melted by heating at 50°C for 5 minutes (Figure 16). The platinum-crosslinked atelocollagen hydrogel crosslinked with the cisplatin-DMSO complex (100 μM cisplatin-DMSO complex) contracted but did not completely melt when heated at 70°C for 5 minutes (Figure 16).

[0084] 16. Evaluation of thermal contraction of hydrogels When immersed in 80°C boiling water, the fibrous atelocollagen hydrogel (0 μM cisplatin-DMSO complex) rapidly melted and diffused into the water (Figure 17; photographs after immersion in boiling water are not shown). This result suggests that the fibrous atelocollagen hydrogel is not crosslinked. A platinum-crosslinked atelocollagen hydrogel crosslinked with the cisplatin-DMSO complex (100 μM cisplatin-DMSO complex) contracted when immersed in 80°C boiling water (Figure 17). This result suggests that the platinum-crosslinked atelocollagen hydrogel is crosslinked.

[0085] 17. Cytotoxicity Assessment Almost no dead cells were observed in both the fibrous atelocollagen hydrogel and the platinum-crosslinked atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex (Figure 18). Furthermore, when comparing the cell morphology after 1.5 hours of culture, multiple thin processes were formed in the fibrous atelocollagen hydrogel, whereas cell elongation and stress fibers were formed in the platinum-crosslinked atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex (not shown).

[0086] Furthermore, the cell proliferation activity on the platinum-crosslinked atelocollagen hydrogel crosslinked with the cisplatin-DMSO complex was approximately two times higher than that on the fibrous hydrogel (FIG. 19).

[0087] 18. Evaluation of cell infiltration Cell infiltration was observed in both the fibrous atelocollagen hydrogel and the platinum-crosslinked atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex, suggesting that the platinum-crosslinked atelocollagen hydrogel has biocompatibility equivalent to or greater than that of the fibrous atelocollagen hydrogel (Figure 20).

[0088] III. Evaluation as a Three-Dimensional Cell Culture Substrate Next, the usefulness of the hydrogel consisting of collagen cross-linked with a cisplatin-DMSO complex as a three-dimensional cell culture substrate was evaluated.

[0089] 1. Experimental Method: Subconfluent MDCK cells derived from a canine renal tubular cell line were harvested and resuspended in D-MEM containing 10% (v / v) FBS. The collagen acidic solution, cisplatin-DMSO complex, and cell suspension were mixed to final concentrations of 4 mg / mL collagen, 100 μM cisplatin-DMSO complex, and 4 × 10 3 The mixture was mixed to a concentration of 1000 cells / mL. This mixture was added to a 35-mm glass dish and incubated at 37°C for 45 minutes to allow gelation. Two mL of medium was then added to the dish, and the medium was changed every two days. After 6 days of culture, the cells were fixed with 4% (v / v) p-formaldehyde / phosphate buffer for 15 minutes, permeabilized with 0.1% (v / v) Triton X-100 / PBS for 15 minutes, and blocked with 1% (w / v) BSA / PBS for 30 minutes. Nuclei and F-actin were stained with Hoechst 33342 and Phalloidin-iFluor 488 (AT Bioquest, Pleasanton, CA), respectively, for 3 hours, and fluorescent images were obtained using a Fluoview FV-1000 fluorescence confocal microscope (Olympus). The fluorescence intensity of five different nuclei in the cross-sectional images of the cell clusters was quantified using ImageJ (version 1.52a) and plotted against the depth from the bottom of the gel. The fibrous atelocollagen hydrogel was used as a control for comparison.

[0090] 2. Results Figure 21 shows fluorescence images of MDCK cell clusters in a platinum-crosslinked atelocollagen hydrogel crosslinked with a cisplatin-DMSO complex (hereinafter referred to as "platinum(II) complex-crosslinked gel" or "PCG"). MDCK cells were embedded in 4 mg / mL fibrous atelocollagen hydrogel (Figure 21A; hereinafter referred to as "fibrous gel" or "FG") or PCG (Figure 21B). After 6 days of culture, the cells were fixed and stained with Hoechst 33342 and Phalloidin-iFluor 488. The cells were observed under a confocal fluorescence microscope. Blue and green staining represent nuclei and F-actin, respectively. The depth of the cell cluster from the bottom of the dish is indicated in the image. The scale bar represents 50 μm.

[0091] In the case of fibrous gels, it is difficult to obtain fluorescent images of F-actin and nuclei at a depth of 739 μm, but in the case of the gel of the present invention shown in the right figure, good fluorescent images could be obtained even at a depth of 803 μm.

[0092] Figure 21C shows the relationship between cell depth and fluorescence intensity. Nuclear fluorescence intensity in cell clusters was measured and plotted against depth. Each plot shows the mean ± standard deviation (n = 5).

[0093] It was revealed that the gel of the present invention exhibits less decrease in fluorescence intensity even at greater depths than ordinary gels, and is therefore visible.

[0094] IV. Gel Dissolution Method 1. Experimental Method 200 μL of 2.5 mg / mL atelocollagen gel containing 100 μM cisplatin-DMSO complex was prepared in a 1.5 mL tube, to which 200 μL of 0.4 M reduced glutathione / PBS was added and allowed to stand at room temperature. A stainless steel ball was placed on top of the gel to examine its dissolution before the addition of the glutathione solution, and 3 and 24 hours after the addition of the glutathione solution.

[0095] 2. Results The results are shown in Figure 22. The arrowhead indicates the position of the stainless steel ball. Before the addition of the glutathione solution, the stainless steel ball was held on the surface of the hydrogel. However, 3 hours after the addition of the glutathione solution, the stainless steel ball began to sink due to dissolution of the hydrogel, and 24 hours after the addition of the glutathione solution, the stainless steel ball had completely sunk.

[0096] This indicates that the hydrogel of the present invention can be decrosslinked and dissolved by adding reduced glutathione, a thiol compound. This result clearly differs from other crosslinking methods, making it possible to recover spheroids cultured in the gel and to remove the gel created in the body depending on the situation.

[0097] V. Gel Hardness Control Method (1) 1. Experimental Method A 5 mm thick silicone sheet with a 10 mm diameter hole was placed on Parafilm, and 4 mg / mL atelocollagen gels containing various concentrations of transplatin-DMSO were prepared in the holes. The silicone sheet was removed, and the gel was pressed down from above with a spatula.

[0098] 2. Results The results are shown in Figure 23. When the transplatin-DMSO complex was added in an amount of 50 μM, the gel shook when vibrated, deformed when pressed from above, and was quite sticky. When the transplatin-DMSO complex was added in an amount of 100 μM, the gel hardly shook when vibrated, but deformed when pressed from above, but returned to its original shape. When the transplatin-DMSO complex was added in an amount of 300 μM, the gel did not shook when vibrated, but deformed slightly and returned to its original shape when pressed from above. When the transplatin-DMSO complex was added in an amount of 500 μM, the gel did not shook when vibrated, but deformed slightly and returned to its original shape when pressed from above. When the transplatin-DMSO complex was added in an amount of 1000 μM, the gel did not shook when vibrated, but deformed slightly and returned to its original shape when pressed from above. The gel deformation decreased and the resilience increased depending on the transplatin-DMSO complex concentration. This demonstrates that the hardness of the hydrogel of the present invention can be adjusted by adjusting the concentration of the transplatin-DMSO complex.

[0099] VI. Method for Controlling Gel Stiffness (2) 1. Experimental Method: 4.0 mg / mL atelocollagen gels containing 0, 50, 100, 200, 400, and 800 μM transplatin-DMSO complex were prepared in a 24-well plate. An 8 mm diameter cylinder was pressed into the gel at a speed of 1 mm / min, and the stress was measured using a universal testing machine (UCT-500, A&D). The slope of the stress-strain curve in the elastic region was calculated as the elastic modulus. Each bar represents the mean ± standard deviation (n = 3).

[0100] 2. Results The results are shown in Figure 24. When the amount of transplatin-DMSO complex added was between 50 μM and 400 μM, the elastic modulus of the gel increased depending on the concentration, reaching a plateau at concentrations of 400 μM or higher. This indicates that the hardness of the gel can be adjusted within the range of transplatin-DMSO complex concentrations up to 400 μM.

[0101] VII. Summary From the above results, the hydrogel of the present invention has the following characteristics: - high transparency; - gel formation can be controlled by pH; - gel strength can be controlled by the concentration of platinum(II) complex; - gelation is reversible and the gel can be dissolved; - unreacted crosslinker can be removed.

[0102] This offers the following advantages over conventional collagen gels: (1) Even in thick 3D cultures, cell observation is easy and good data can be obtained efficiently. (2) After being injected into a living body, such as the eyeball, and gelling, it can be dissolved and removed. (3) The hardness of the gel can be adjusted to suit the application, which is expected to enable adjustment of biodegradability. (4) There is no toxicity due to unreacted crosslinker.

[0103] The hydrogel of the present invention can be used as a medical material such as a material for treating ophthalmic diseases, an artificial vitreous body, a hemostatic agent (preferably a tamponade material), a sustained-release drug carrier, or a material for replacing tissue defects, and as a research material such as a scaffold substrate for cell culture.

Claims

1. A hydrogel consisting of platinum-crosslinked collagen in which collagen is crosslinked with a platinum (II) complex, and having a visible light transmittance of 60% or more as measured at an absorbance of 400 nm in a cell with an optical path length of 10 mm.

2. The hydrogel according to claim 1, which comprises platinum-crosslinked collagen in which collagen is crosslinked with a platinum (II) complex, and which has a visible light transmittance of 60% or more as measured at absorbance from 380 nm to 780 nm in a cell having an optical path length of 10 mm.

3. The hydrogel of claim 1, wherein the platinum(II) complex contains dimethylsulfoxide (DMSO) as a ligand.

4. The hydrogel according to claim 3, characterized in that the platinum(II) complex is a complex in which at least one of the chloride ion and / or ammine ligands of cis-diamminedichloroplatinum(II) (cisplatin) and / or trans-diamminedichloroplatinum(II) (transplatin) is replaced with DMSO.

5. The hydrogel according to claim 1, characterized in that the collagen is atelocollagen.

6. The hydrogel according to any one of claims 1 to 5 for use as an artificial vitreous body, a hemostatic agent, a sustained-release drug carrier, a material for replacing tissue defects, or a scaffold material for cell culture.

7. A material for treating ophthalmic diseases, comprising the hydrogel according to any one of claims 1 to 5.

8. An artificial vitreous body comprising the hydrogel according to any one of claims 1 to 5.

9. A hemostatic agent comprising the hydrogel according to any one of claims 1 to 5.

10. A scaffold material for cell culture, comprising the hydrogel according to any one of claims 1 to 5.

11. A method for producing the hydrogel according to any one of claims 1 to 5, comprising the step of mixing collagen and a platinum (II) complex and incubating the mixture.

12. The method according to claim 11, comprising the step of incubating the collagen having a concentration in the range of 1.0 to 4.0 mg / mL and the platinum (II) complex having a concentration in the range of 25 μM to 1 mM in an environment having a pH in the range of 5.0 to 8.

0.

13. A method for producing the hydrogel according to any one of claims 1 to 5, comprising the steps of: (a) incubating collagen having a concentration in the range of 1.0 to 4.0 mg / mL and a platinum (II) complex having a concentration in the range of 25 μM to 1 mM in an environment with a pH of less than 5.0; and (b) changing the pH environment to 5.0 to 8.0 to induce gelation.

14. The method of claim 13, further comprising, between steps (a) and (b), a step (a') of removing free platinum(II) complexes by dialysis in an environment having a pH of less than 5.0.

Citation Information

Patent Citations

  • Aqueous collagen solution and gel obtained therefrom

    JP2014103985A

  • Gel material for ophthalmological treatment

    JP2017121307A

  • Hydrogel composition

    JP2020150846A

  • Collagen gel and process for producing the same

    WO2005079879A1

  • Cross-linked collagen and uses thereof

    WO2008147867A2